A Preclinical Evaluation of Antrodia camphorata Alcohol Extracts in the Treatment of Non-Small Cell Lung Cancer Using Non-Invasive Molecular Imaging by Chiou, Jeng-Feng et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 914561, 12 pages
doi:10.1093/ecam/nep228
Original Article
APreclinicalEvaluationofAntrodiacamphorata AlcoholExtracts
in the Treatmentof Non-SmallCellLungCancer Using
Non-Invasive MolecularImaging
Jeng-Feng Chiou,1,2,3 Al e xand e rT .H.W u, 1,3 Wei-Tin Wang,4 Tsu-HsiangKuo,4
Juri G. Gelovani,5 I-HsinLin,6 Chih-HsiungWu,7 Wen-Ta Chiu,7 andWin-PingDeng4,8
1Cancer Center and Department of Radiatioin Oncology, Taipei Medical University Hospital, Taipei, Taiwan
2Institute of Medical Sciences, National Defence Medical Center, Taipei, Taiwan
3Department of Radiation, School of Medicine, Taipei Medical University, Taipei, Taiwan
4Graduate Institute of Biomedical Materials and Engineering, Taipei Medical University, 250 Wu-Hsing Street,
Taipei 110, Taipei, Taiwan
5University of Texas M.D Anderson Cancer Center, Houston, TX, USA
6Institute of Traditional Medicine, Chung-Gung University, Taipei, Taiwan
7Department of Surgery, School of Medicine, Taipei Medical University and Hospital, Taipei, Taiwan
8Stem Cell Research Center, Taipei Medical University, Taipei, Taiwan
Correspondence should be addressed to Win-Ping Deng, wpdeng@ms41.hinet.net
Received 25 June 2009; Accepted 4 December 2009
Copyright © 2011 Jeng-Feng Chiou et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
This study was carried out to provide a platform for the pre-clinical evaluation of anti-cancer properties of a unique CAM
(complementary and alternative medicine) agent, Antrodia camphorata alcohol extract (ACAE), in a mouse model with the
advantageous non-invasive in vivo bioluminescence molecular imaging technology. In vitro analyses on the proliferation,
migration/invasion, cell cycle and apoptosis were performed on ACAE-treated non-small cell lung cancer cells, H441GL and
control CGL1 cells. In vivo, immune-deﬁcient mice were inoculated subcutaneously with H441GL followed by oral gavages of
ACAE. The eﬀect of ACAE on tumor progression was monitored by non-invasive bioluminescence imaging. The proliferation and
migration/invasion of H441GL cells were inhibited by ACAE in a dose-dependent manner. In addition, ACAE induced cell cycle
arrest at G0/G1 phase and apoptosis in H441GL cells as shown by ﬂow cytometric analysis, Annexin-V immunoﬂourescence and
DNA fragmentation. In vivo bioluminescence imaging revealed that tumorigenesis was signiﬁcantly retarded by oral treatment
of ACAE in a dose-dependent fashion. Based on our experimental data, ACAE contains anti-cancer properties and could be
considered as a potential CAM agent in future clinical evaluation.
1.Introduction
It is now generally accepted that human cancer is the
result of a culmination of genetic mutations, which lead to
abnormal/pathological signaling pathways contributing to
its development and malignancy. For instance, mutations in
closeto200geneshavebeenrecentlydescribedinalandmark
study of human breast and colorectal cancers [1]. This study
raises concerns that monofunctional targeted drugs will not
cure most common carcinomas. The number of genes that
might contribute to carcinogenesis could be much higher
as mutations in non-coding regulatory regions of coding
genes were not detectable by the methods employed in
this study, nor were relative large deletions and insertions,
ampliﬁcations and translocations. Lung cancer in particular
has consistently ranked the leading cause of cancer death
for both men and women globally. Two main molecular
targets, KRAS and EGFR have been shown to attribute to
the development of lung carcinoma and various targeted
therapeuticagentshavebeendevelopedagainstthesetwokey2 Evidence-Based Complementary and Alternative Medicine
molecules [2]. However, cancer cells often develop resistance
rendering treatments ineﬀective, indicating the existence of
additional signalling pathways and reﬂecting the complexity
of lung cancer etiology. Therefore, the genetic complexity
of human cancers warrants the needs to develop new
multifunctional drugs to be used either for the prevention
or treatment of disease.
Complementary and alternative medicine (CAM) has
emerged as an important part of integrative medicine in
the management of cancer. Many natural substances have
been explored for their unique properties in the treatment
of inﬂammation-related diseases including cancer. Antrodia
camphorata (AC), a Ganoderma-like fungus of the Polypo-
raceae Basidiomycotine family, has been widely used as a
folk medicine in Taiwan for a variety of ailments includ-
ing abdominal pain, diarrhea, hypertension and suggested
to contain anti-inﬂammatory, anti-oxidative and immune
modulating eﬀects [3, 4]. Because wild AC fruiting bodies
are very scarce and expensive, artiﬁcially cultivated forms
have been developed as an alternative. Two major methods
for AC cultivation include solid-state culture and liquid-state
fermentation. Several bioactive ingredients have been iden-
tiﬁed in AC including triterpenoid sesquiterpene lactone,
steroid and polysaccharides [5–8]. Among these ingredients,
triterpenoid has been most studied and demonstrated to
exert potent anti-inﬂammatory and anti-tumorigenic eﬀects
both in vitro and in vivo [9, 10]. Mechanistically, puriﬁed
or synthetic triterpenoids such as oleanolic acid (OA) and
ursolic acid (UA) have been suggested to exert their anti-
tumor and cytoprotective eﬀects via a collection of diﬀerent
molecular targets including KEAP1 (the inhibitor of the
transcription factor, NRF2), IκB kinase, TGFβ and STAT
signaling pathways. In this regard, extracts obtained from
AC represent an ideal new source for the development of
multifunctional drug and may act as contributors to the
observed anti-cancer properties in a complementary fashion
to limit carcinogenesis.
In this study, Antrodia camphorata alcohol extracts
(ACAE) obtained were examined for their anti-cancer prop-
ertiesinanon-smallcelllungcancer(NSCLC)mousemodel.
ACAE appeared to suppress NSCLC tumorigenesis in a dose-
dependent manner. Non-invasive bioluminescence imaging
demonstratedoralgavagesofACAEsigniﬁcantlyretardedthe
growth of subcutaneously inoculated NSCLC cells. Mech-
anistically, we demonstrated that ACAE inhibited NSCLC
tumor growth by promoting cell cycle arrest and inducing
caspase 3-mediated cellular apoptosis. This study provides
rationale and platform for future clinical evaluations of
ACAE for the management of NSCL carcinomas.
2. Methods
2.1. Preparation of ACAE. The artiﬁcial culture community
of AC fruiting bodies was provided by Well Shine Biotech-
nology Development Co. (Taipei, Taiwan.) The ﬁne powders
of AC fruiting bodies were mixed with 95% ethanol in a
1:20 (w/v) ratio and shaken for 24h at room temperature.
The supernatant of extracts was further ﬁltered by a 0.2mm
pore size ﬁlter paper (Millex GP Carrigtwohill, Cork, Ire-
land), centrifuged at 3000r.p.m. for 30min to remove the
precipitate, and then the extracts were lyophilized and stored
at −20◦C before use.
2.2. Cell Lines. The H441GL cell line was a generous gift
from Dr Gelovani’s laboratory (University of Texas M.D
Anderson Cancer Center, Houston, TX, USA). Brieﬂy, H441
cells originally obtained from the American Type Culture
Collection (ATCC) catalogue number: HTB-174. Double
reporter genes, enhanced green ﬂuorescent protein (G) and
ﬁreﬂy luciferase (L) were integrated permanently into the
genome of these cells for non-invasive in vivo cell tracking
purpose. The control cell line, CGL1 [11, 12]w a sp r o v i d e d
by Dr John-Leslie Redpath from Department of Radiation
Oncology, University of California at Irvine, Irvine, CA,
USA.
2.3. RNA Extraction and Semi-Quantitative PCR Analysis.
Total RNA extraction of harvested cells from subconﬂuent
monolayer cultures were extracted using reagent (TRIzol;
Invitrogen Life Technologies) and undergone reverse tran-
scription (RT) followed by PCR ampliﬁcation. Reverse tran-
scription was performed with SuperScript III (Invitrogen
Life Technologies) and an Oligo (dT)12−18 primer. Four
micrograms of RNA were added into a ﬁnal volume of 21μL
solution containing 10mM deoxynucleotide triphosphate
mix, 10 × RT buﬀer, 25mM MgCl2, 0.1M dithiothreitol,
RNase inhibitor and RNase H. Four micrograms of RT prod-
uct were used for the PCR ampliﬁcation in a ﬁnal volume
of 25μL containing 2.5mM deoxynucleotide triphosphate,
25mM MgCl2, upstream or downstream primers, and
Taq DNA polymerase (Invitrogen Life Technologies). PCR
ampliﬁcation of reverse-transcribed cDNA was performed
withthefollowingprimers(forward,Fandreverse,R).RB,F:
CAT CTA ATG GAC TTC CAG AG; R: CAT AAC AGT CCT
AAC TGG AG. p53, F: CAG CCA AGT CTG TGA CTT GCA
CGT AC; R: CTA TGT CGA AAA GTG TTT CTG TCA TC.
p21,F:ATGTCAGAACCGGCTGGGGATG;R:TTAGGG
CTT CCT CTT GGA GAA G. Cyclin D1, F: CGA GGA GCT
GCT GCA AAT GG; R: GGT ATC AAA ATG CTC CGG AGA
GG. Cyclin E, F: ACT GAC TGC TGC TGC CTT GTG C. R:
T C GG T GG T GT C AT A AT G CC T CC .C y c l i nA ,F :G A G
CTA TCC TCG TGG ACT GG; R: GCC CAC AAG CTG AAG
TTT TC. CXCR4, F: TTC TAC CCC AAT GAC TTG TG; R:
ATG TAG TAA GGC AGC CAA CA. Internal control primers
used were: GAPDH, F: GCT CTC CAG AAC ATC ATC CCT
GCC; R: CGT TGT CAT ACC AGG AAA TGA GCT T. β-
actin, F: CGG AAC CGC TCA TTG CC; R: ACC ACT GTG
CCC ATC TA.
2.4. Western Blots. Cell lysates were prepared by treating the
cells for 30 min in RIPA lysis buﬀer (1 × PBS, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), protease inhibitor cocktail (Pierce, Rockford,
IL, USA). The lysates were centrifuged at 12000r.p.m. for
5min and the protein concentration in the supernatant
was determined using a BCA protein assay kit (Pierce,Evidence-Based Complementary and Alternative Medicine 3
Rockford, IL, USA). Equal amounts of proteins were
separated, respectively, by 10% of SDS-polyacrylamide gel
electrophoresis and followed by electro-transfer to a PVDF
membrane. The membrane was blocked with a solution
containing 4% nonfat dried milk TBST buﬀer (20mM Tris-
HCl pH 7.4, 150mM NaCl and 0.1% Tween 20) for 1h and
washed with TBST buﬀer. Protein expression was monitored
by immunoblotting using speciﬁc primary antibodies and
respectivesecondaryantibodies.Caspase3,cylcinsA,D1and
E were purchased from Santa Cruz Biotechnology; cleaved
caspase 3 and caspase 9 from Cell Signaling. CXCR4 from
AbCam and p53 were from Novocastra, while p21 and RB
werefromUpstatebiotechnology.Theincubationconditions
were carried out as indicated by the vendor. The signals were
visualized using an ECL chemiluminescence kit (Amersham,
USA) and UVP imaging system (Upland, CA, USA).
2.5. Cell Viability Assay. Inhibition concentration 50%
(IC50) for cell viability of ACAE was measured by MTT
assay based on the ability of live cells to convert tetrazolium
salt into purple formazan. Cells were seeded into 96-well
dishes (3 × 103 cells/well) with medium containing ACAE at
concentrations ranging from 0 to 300μgmL −1 for 48h. After
treatment for the indicated times, 20μLo fM T Ts o l u t i o n
(Merck, Darmstadt, German) was added to each well and
the plate was incubated at 37◦C for 4h. After the removal
of medium, 200μL of DMSO was added to each well and
the plate was gently shaken for 5min. The absorbance was
determined at 540nm. The cell viability ratio = OD of
experimental groups/OD of control groups.
2.6. Colony Forming Assay. Both H441GL and CGL1 cells
were treated with medium containing ACAE at concentra-
tions ranging from 0 to 300μgmL for 48h. Cells were then
harvested and seeded in 10cm culture dish at a density
of 500 cell/dish. Fresh culture medium (without ACAE)
w a sr e p l a c e do nd a y7a n da p p r o x i m a t e l yo nd a y1 0c e l l
colonies were formed. Cells were then ﬁxed using 4%
paraformaldehyde and stained with Crystal violet colony
counts.
2.7. Cell Scratch Wound Healing Assay. The wound healing
assay was performed accordingly. Brieﬂy, when H441GL
cells became conﬂuent in a 24-well plate, a wound was
made with a sterile tip. Cells were washed with serum-free
medium and further incubated in RPMI1640 with 1% FBS
with various concentration of ACAE for 12h. The distance
of cell migration at 12h and 24h was determined from
the photographed images. Wound size% = (wound size at
observed time/initial wound size) × 100%.
2.8. Migration Assay. At o t a lo f1× 105 H441GL cells were
seeded into the upper Transwell chamber (6.5mm diameter
with a pore size of 8mm; Corning, Inc.) while in the lower
chamber, 800mL RPMI1640 with 10% FBS was added and
theassaywasdonefor24hat37◦Cand5%CO2.Atindicated
timepoints,cellswereﬁxedwith3%formaldehydeandﬁlters
were stained with the hematoxylin (Sigma,Inc). Cells that
had not migrated from the upper side of the ﬁlters were
scraped oﬀ with a cotton swab, The number of cells that
had migrated to the lower side of the ﬁlter were counted
under a light microscope with ﬁve high-power ﬁelds (200×).
Experiments were done in triplicate.
2.9. Gelatin Zymography. Gelatin zymography was per-
formed for both serum free medium control and serum
free medium of H441GL with ACAE treatment. SDS-PAGE
(7.5% acrylamide and 0.1% gelatin, Sigma-Aldrich) was
loaded with 15μL of total collected culture medium per lane.
Electrophoresis was carried out at a constant voltage of 70
V, until the dye reached the bottom of the gel. Following
electrophoresis, gels were washed in renaturation buﬀer
(2.5%TritonX-100in50mMTris-HCl(pH7.5))for1hwith
shaking. The zymograms were the incubated for 18h at 37◦C
in incubation buﬀer (0.15M N aCl, 10mM CaCl 2, 0.02%
NaN3 in 50mM Tris-HCl (pH 7.5)) Gels were then stained
with Coomassie blue and destained with 7% methanol and
5% acetic acid. Areas of enzymatic activity appeared as clear
bands over the dark background.
2.10. Cell Cycle Analysis. Flow cytometry analysis of PI-
stained cells was performed to demonstrate the eﬀect of
AC on cell cycle progression. Brieﬂy, 2 × 106 H441GL
cells were cultured in 10cm dish and treated with 0, 50,
100, 150μgmL −1 concentrations of ACAE, respectively. Cells
were harvested after 48h of treatment, trypsinized, washed
andﬁxedin70%ethanolfor30min.Afterﬁxation,cellswere
resuspended in 1mL propidium iodide (PI) staining buﬀer
(0.1% TritonX-100, 100mgmL−1 RNase A, 500mgmL−1 PI
in PBS) at 37◦C for 30 min and the proportion of cells in a
particular phase of cell cycle was determined by CellQuest
software (FACS Calibur, BD Biosciences, USA).
2.11. Annexin V-FITC Flow Cytometric Analysis. Annexin
V-FITC apoptosis detection kit (BD Biosciences) was used
to detect early and late apoptosis. Annexin V has a strong
aﬃnity for phosphatidyl serine which is externalized in the
membranesofapoptoticcells.Inbrief,after48hoftreatment
with ACAE (0, 50, 100 and 150μgmL −1), cells were washed
in PBS and resuspended in binding buﬀer (HEPES-NaOH
10mM pH 7.4, 144mM NaCl and 25mM CaCl2). Annexin
V-FITC (0.2 μg/μL) and PI (0.05μg/μL) were added and
incubated in dark for 20 min. Cells were then subjected
to FACS analysis. At least 10000 events were recorded and
represented as dot plots. Data were analyzed by using FCS
V3 software.
2.12. Tumor Xenografts and In Vitro Molecular Imaging.
Tumour xenografts were established by subcutaneous injec-
tion of H441GL cells (1 × 105 cells in 100μL PBS) into three
groups of severe combined immunodeﬁcient, CB17-SCID
female mice and each group contained at least four animals.
The ﬁrst group (as the control group) received subcutaneous
injection of H441GL cells (1 × 105 cells in 100μL PBS)
withoutanyfurthertreatments.Thesecondandthirdgroups
receivedoralgavagesofACAE150μg(6.25mgkg−1 3days −1)4 Evidence-Based Complementary and Alternative Medicine
and 500μg (31.25 mgkg−1 3d a y s −1), respectively, after
tumor inoculation. Tumor volume was detected by using
an in vivo non-invasively optical imaging system (IVIS-
200, Xenogen Corp., Alameda, CA, USA). At the end of
the experiment, the mice were humanely sacriﬁced. Animal
care and euthanasia were done with the approval of the
Institutional Animal Care and Use Committee (IACUC) at
Taipei Medical University.
3. Results
3.1. ACAE Poses Anti-Proliferative Eﬀect on NSCLC Cell Line
H441GL Cells. To investigate the potential usage of ACAE in
the treatment of lung cancer, NSCLC cell line H441GL and
controlCGL1cellsweretreatedwithdiﬀerentconcentrations
of ACAE for the examination of ACAE’s eﬀect on these cells.
In response to ACAE treatment, H441GL cells exhibited an
elongated morphology with irregular cytoplasmic volume
and decreased cell density (Figure 1(a), upper panel). In
contrast, the morphology of CGL1 cells remained unaﬀected
even at the highest concentration of ACAE (Figure 1(a),
lower panel), suggesting that ACAE functions on physi-
ological deregulated cells. Next, the proliferation proﬁles
of ACAE-treated H441GL and control CGL1 cells were
examined and compared. After a 48h incubation period, the
total number of H441GL cells decreased as the concentration
of ACAE increased while CGL1 cells remained relatively
unaﬀected (Figure 1(b)). Similarly, data from the MTT
survival and colony forming eﬃciency, both indices for cell
proliferation, exhibited a negative correlation between the
MTT survival ratio (Figure 1(c)), colony forming eﬃciency
(Figure 1(d)) and the concentration of ACAE.
3.2. Promotion of Cell Cycle Arrest in H441GL Cells by ACAE
Treatment. Next, we examined whether ACAE-mediated
anti-proliferative eﬀect on H441GL cells was the result of cell
cycle arrest. ACAE-treated H441GL and control CGL1 cells
underwent ﬂuorescence-activated cell sorting (FACS) anal-
ysis. At 150μgmL −1 of ACAE treatment, the proportion of
H441GLcellsincreasedinG0/G1phase(from67.02 ±5.11%
to 77.10 ± 1.48%) while decreased in G2/M phase (from
18.84 ± 2.31% to 8.13.10 ± 1.59%), an ∼10% phase shift
when compared to non-treated H441GL cells (Figure 2(a)).
In comparison, CGL1 cells appeared to be unaﬀected by
ACAE treatment because the percentage of cells in each
stage of division cycle remained approximately unchanged
(Figure 2(b)). We also analyzed the expression proﬁles of
several key cell cycle regulatory proteins including p53, RB,
p21, cyclins D1, E and A using both semi-quantitative PCR
and western blotting techniques. No signiﬁcant changes in
mRNA and protein levels in H441GL cells across the ACAE
concentration spectrum examined (Figure 2(c)). However,
at the highest concentration ACAE (150μgmL −1), the
expression level of cyclin E was found increased while cyclin
A decreased (Figure 2(c), left), which corroborated to the
increased percentage of cells in G0/G1 phase and decreased
proportion of cells in G2/M phase, respectively. Data from
western blot analysis were quantitatively represented in fold
changes (Figure 2(c), right).
3.3. Induction of Apoptosis in ACAE-Treated H441GL Cells.
After establishing that the addition of ACAE to H441GL
cells inhibited their proliferation and caused cell cycle arrest,
we then investigated the possibility of ACAE in triggering
apoptosis in H441GL cells. After 48h treatment of vari-
ous concentrations of ACAE, genomic DNA samples were
collected from both H441GL and CGL1 cells. At 100 and
150μgmL −1, ACAE was able to induce DNA fragmentation
in H441GL cells but not in CGL1 cells (Figure 3(a)).
In supportive of these data, ACAE-treated H441GL cells
exhibited a concentration-dependent increase in Annexin-
V ﬂuorescence signal when examined by ﬂow cytometric
method where an ∼9-fold increase in Annexin-V signal
was detected in H441GL cells treated with 150μgmL −1 of
ACAE (Figure 3(b)). Furthermore, we demonstrated a dose-
dependent up-regulation of both caspases 9 and 3 in ACAE-
treated H441GL cell lysates (Figure 3(c)). Results from
theseaforementionedexperimentsindicatedACAEtriggered
apoptosis in H441GL cells.
3.4. Retardation of Migratory Ability of H441GL Cells
P r o m p t e db yA C A ET r e a t m e n t .One of the desirable traits
of an anti-cancer agent is the ability to suppress cellular
migration. Thus, we set to examine if ACAE could function
in modulating migratory ability in H441GL cells. When
H441GL cells were treated with various concentrations of
ACAE for 12 and 24h in wound scratch assay, the migratory
ability of H441GL cells was increasingly suppressed as
the concentration of ACAE elevated (Figure 4(a), left).
Overnight treatment of ACAE at 150μgmL −1 resulted in an
∼60% inhibition on H441GL cells’ migratory ability when
compared to the control group (Figure 4(a), right). Since
CXCR4/SDF-1chemotacticaxisisinstrumentalinregulating
m i g r a t i o ni nm a n yd i ﬀerent cell types, we examined if
ACAE-mediated migration suppression was via this axis.
Both mRNA and protein expression level of CXCR4 in
H441GL cells were reduced by ACAE incubation in a
concentration-dependentfashion(Figure4(b),leftandright,
resp.). Approximately a 2-fold decrease in CXCR4 expression
level was achieved by ACAE at 150μgmL −1 (Figure 4(b),
right). The invasiveness of H441GL cells was also suppressed
by the addition of ACAE as demonstrated by trans-well
analysis (Figure 4(c), left). The decreased invasive ability
of H441GL cells was coined with the decreased enzymatic
activity of both MMP2 and MMP9 as shown by zymography
(Figure 4(c), right).
3.5.Non-InvasiveInVivoMonitoringofACAE-MediatedAnti-
tumor Eﬀects on H441GL Tumor-Bearing Mice. The anti-
tumor eﬀect of ACAE was further veriﬁed in H441GL-
inoculated mice. H441GL cells were genetically modiﬁed
to contain enhanced green ﬂuorescence protein and ﬁreﬂy
luciferase so that in vivo bioluminescence imaging was madeEvidence-Based Complementary and Alternative Medicine 5
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Figure 1: ACAE treatment inhibited the proliferation of H441GL cells. (a) ACAE treatment inhibited H441GL cell growth in a dose-
dependent manner but not in CGL1 control cells. ACAE-treated H441GL cells exhibited an abnormal and elongated morphology, while
the CGL1 cells remained a normal physiological appearance even at the highest employed concentration of 150μgmL −1. ACAE-mediated
anti-proliferativeeﬀectwasfurtherdemonstratedquantitativelybythecellnumber(b),MTTsurvivalratio(c)andcolonyformingeﬃciency
ratio (d) in both H441GL and CGL1 cells. All assays were performed in triplicates and the results were shown as mean ± SD.6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: ACAE treatment for 48h promoted cell cycle arrest in H441GL cells. Representative cell cycle proﬁles of ACAE treated H441GL
(a) and CGL1 (b) cells, respectively, demonstrating arrest in G0/G1 phase. X-axis (FL2-A) represents cells stained positive for PI while the
Y-axis for cell counts. The percentage of cells in each phase is as indicated. (c) Cell cycle regulator molecules at transcriptional ((c), left)
and translational ((c), middle) levels were examined. No signiﬁcant diﬀerences were observed at the transcriptional level. However, cyclin
A protein expression level decreased while cyclin E increased at 150μgmL −1 of ACAE. Quantitative data representation of western blotting
experiments in ((c), right). Each experiment was performed in triplicates (∗P < .05, ∗∗P < .01).Evidence-Based Complementary and Alternative Medicine 7
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Figure 3: Induction of apoptosis in H441GL cells by ACAE treatment. (a) DNA agarose gel analysis. Genomic DNA samples were obtained
from H441GL cells after incubation with diﬀerent concentrations of ACAE. DNA fragmentation was observed in samples incubated with
100 and 150μgmL −1 of ACAE, whereas DNA samples from CGL1 cells remained intact. Approximately 5μgo fD N As a m p l e sw e r el o a d e d
in each lane. (b) Induction of apoptosis was analyzed by ﬂow cytometry with anti-Annexin-V antibody. The intensity of Annexin-V signal
in the H441GL cells increased as the concentration of ACAE increased. Quantitatively, the intensity of Annexin-V ﬂuorescence detected in
H441GL cells 48h post-ACAE treatment was concentration dependent (lower panel, ∗P < .05; ∗∗P < .01). (c) Eﬀect of ACAE on apoptotic
pathways in H441GL cells. H441GL cells were treated with various concentrations of ACAE for 48h. A concentration-dependent activation
of both caspas-9 and its eﬀector caspase-3 and the down-regulation of Bcl-2 were observed.
possible. Initially, the bioluminescence of H441GL was com-
pared to that of parental H441 cells. H441GL cells demon-
strated a substantially higher magnitude of bioluminescence
when compared to their parental cells (Figure 5(a)). In addi-
tion,thepossibilitythatACAEtreatmentcouldinterferewith
ﬁreﬂy luciferase and its substrate, luciferin was eliminated
by in vitro bioluminescence assay. Bioluminescent activity of
H441GL cells was not altered under diﬀerent concentrations
of ACAE after a brief incubation period (Figure 5(b)).
After validation of our bioluminescence system, mice were
then inoculated with 105 H441GL cells subcutaneously
and received oral gavages of ACAE at 100μg and 500μg
(equivalent to 6.25mgkg−1 3d a y s −1 and 31.25 mgkg−1 3
days−1,r e s p . )a st r e a t m e n t .I ti sc l e a rt h a tA C A Et r e a t m e n t
at 100μg (Figure 5(c), middle row) signiﬁcantly reduced
the tumour burden when compared to that of control
group (Figure 5(c),u p p e rr o w ) .A tah i g h e rc o n c e n t r a t i o n ,
500μg, tumor regression was signiﬁcant to the level where8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: In vitro inhibition of migration/invasiveness of H441GL cells by ACAE. (a) Wound-scratch assay data revealed that ACAE exerted
a dose-dependent inhibitory eﬀect on H441GL invasive ability after 24h treatment period. Bar, 500μm (left). Quantitatively, at 150μgmL −1
of ACAE, a 60% of motility inhibition was observed (right, ∗P < .05; ∗∗P < .01). (b) Semi-quantitative analysis of ACAE-treated H441GL
cell lysate demonstrated that CXCR4 transcript level (left) was down-regulated at 150μgmL −1 of ACAE. The lower part represents data
expressed quantitatively by densitometric means. Western blot analysis of ACAE-treated H441GL cell lysate probed with anti-CXCR4
antibody (right). CXCR4 expression was down-regulated by ACAE treatment in a concentration-dependent manner. When represented
quantitatively (lower), 150μgmL −1 of ACAE exhibited the greatest suppression of CXCR4 expression (∗∗P < .01). (c) Invasive ability of
H441GL cells was suppressed by ACAE treatment as demonstrated by transwell analysis (left, ∗∗P < .01), while matrix metallo-protease
(MMP) zymography demonstrated (left) that both pro-MMP9 (92kD) and pro-MMP2 (72kD) enzymatic activity in H441GL cells was
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bioluminescent signals from the tumor were undetectable
(Figure 5(c)). The tumor size was also measured using a
caliper. A similar trend was observed in that the tumor
size regressed over the 28-day ACAE treatment regimen
(Figure 5(d)).
4. Discussion
Diﬀerent extraction and cultivation methods of AC have
been developed and they result in diﬀerent enrichment of
bioactive ingredients. For instance, only methanol extracts
from wild and solid-state cultures of AC contained anti-
hypertensive eﬀects in rats but not water extracts [4].
In this study, we aimed to evaluate potential anti-cancer
properties of an AC extract obtained by a newly developed
sequential extraction method involving ethanol, hence it is
given the name ACAE, in a NSCLC mouse model assisted by
bioluminescence imaging.
A NSCLC cell line modiﬁed to contain dual reporter
genes namely green ﬂuorescent protein (G) and ﬁreﬂy
luciferase (L), H441GL, was used as both in vitro and
in vivo model. ACAE exhibits several desirable anti-cancer
properties. First, ACAE extract was shown to inhibit the
proliferation of H441GL in a dose-dependent manner,
supported by MTT and colony forming tests. As the
concentration of ACAE increased, H441GL cells took on a
more elongated shape accompanied by a lower cell density.
According to ﬂow cytometric analysis, ACAE treatment
promoted a cell cycle phase shift from G2/M to G0/G1 in
H441GL cells but not in the control CGL1 cells. Molecularly,
the cessation of proliferation could be attributed to the
decreased expression of cyclin A since its disruption leads
to inhibition of DNA synthesis in mammalian cells [13]. An
increased cyclin E (and a slight decrease in p21 although
not statistical signiﬁcantly) expression proﬁle was observed.
This interesting observation appeared to be contradictory to
the inhibition of proliferation mediated by ACAE because
the over-expression of cyclin E and down-regulation of
p21 often correlates to poorer prognosis in patients with
diﬀerent cancers [14–16]. On the contrary, a previous study
showed that a decreased level of p21 correlated to a survival
advantage in individuals with null p53 ovarian cancer
[17]. This similar phenomenon might provide a partial
explanation in the case of ACAE-treated H441GL cells since
p53 is non-functional in H441GL cells. Another interesting
observation was that no signiﬁcant changes in the expression
ofretinoblastomaprotein,RB(amastermoleculeincellcycle
regulation), in ACAE-treated H441GL cells. The phospho-
rylation status of RB and its signalling partners including
Cdks, p130, p107 as well as E2F transcription factor all play
instrumental roles in the regulation of cell cycle in both
dividing and non-dividing cells [18, 19]. Therefore, further
investigation in the RB-mediated pathways should provide
moreinsightsintothemolecularmechanismsresponsiblefor
ACAE-mediated cell cycle arrest. Nevertheless, non-invasive
in vivo bioluminescence analysis demonstrated a signiﬁcant
suppression of tumor growth in mice s.c. inoculated with
H441GL cells receiving oral treatment of ACAE. At high
dosage (31.25mgkg−1 3d a y s−1 of ACAE), bioluminescent
signals emitted from the tumor were not detectable 28 days
post-inoculation, indicating a strong inhibitory eﬀect of
ACAE on H441GL cells. In addition, even this high dosage,
the animals appeared healthy and active, suggesting its low
cytotoxicity.
The second beneﬁcial property that ACAE oﬀers in
the treatment of NSCLC is the promotion of apoptosis
in H441GL cells. Increased translocation of membrane
phospholipid phosphatidylserine (PS) as represented by
increased Annexin-V-FITC signals and DNA fragmentation
were observed in ACAE-treated H441GL cells, both impli-
cating apoptosis, although the sub-G1 percentage in ACAE-
treated H441GL cells was not signiﬁcantly increased, which
was incompatible with the signiﬁcant DNA ladder shown in
Figure 3(a). This discrepancy is remained to be investigated.
Tofurtherconﬁrmtheapoptosisinduction,weexaminedthe
expression proﬁles of Bcl-2, pro-caspase-9, -3 and activated
forms of caspase-9 and 3. Evidently, Bcl-2 expression was
down-regulated in the presence of increasing concentrations
of ACAE. This decreased Bcl-2 expression was accompanied
by the concomitant decreased levels of pro-caspase-9, -3 and
increased respective activated forms. Thus, ACAE elicited
mitochondria-mediatedapoptosiscouldcontributetotumor
suppression in addition to aforementioned cell cycle arrest.
Finally,anotherimportantanti-cancerpropertyofACAE
is that ACAE retards the migratory ability of H441GL cells
in a dose-dependent manner as demonstrated by the wound
scratch and Trans-well assays. The chemokine receptor
CXCR4 and its cognate ligand, stromal cell-derived factor-
1alpha (SDF-1), regulate cell traﬃcking in many diﬀerent
cell types including lymphocyte, mesenchymal stem cell as
well as metastatic cancer cells [20, 21]. CXCR4 therefore
represents a target for cancer therapy. We observed that
ACAE suppressed CXCR4 protein expression in a dose-
dependent fashion. It has been shown that in a xenograft
mouse model that the down-regulation of CXCR4 leads to
the suppression of mammary tumor growth [22]. Another
study demonstrated that most pancreatic cancer cells (PaCa)
and their stromal ﬁbroblasts express CXCR4 and PaCa-
derived CXCL8/IL-8 and ﬁbroblast-derived CXCR12/SDF-
1 cooperatively induced angiogenesis in vitro by promoting
human umbilical vein endothelial cells (HUVECs) prolif-
eration, invasion and tube formation [23]. Furthermore,
neutralization of SDF-1 by anti-SDF-1 or anti-CXCR4 mon-
oclonalantibodyinpre-clinicalstudiesresultsinasigniﬁcant
decrease of NSCLC metastases [21]. Therefore, ACAE-
mediated down-regulation of CXCR4 expression in H441GL
cells could concertedly contribute to the decreased prolifer-
ation rate and migratory ability. A proposed model summa-
rizing ACAE-mediated anti-cancer properties is depicted in
Figure 6.
Although the exact composition of ACAE is not yet
available, it has been reported and suggested that the major
anti-inﬂammatoryandanti-cancercomponentidentiﬁedare
the triterpenoids [3, 24, 25]. Triterpenoids have been shown
to inhibit proliferation [24, 25] and induce apoptosis [26–
30] in bronchial epithelial cells and NSCLC. Triterpenoids,
especially oleanolic acid (OA) and ursolic acid (UA) are10 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Non-invasive in vivo bioluminescence evaluation of ACAE-mediated anti-tumor eﬀect. (a) In vitro bioluminescence examination
of H441GL cells. H441GL cells demonstrated a substantially higher level of bioluminescence than control H441 cells. The insert depicts
H441 control and H441GL cells under ﬂuorescence microscope (GFP used for cell-sorting purpose). (b) ACAE treatment does not interfere
with ﬁreﬂy luciferase activity in H441GL cells. (c) Control animals inoculated (s.c) with 105 H441GL cells, receiving vehicle treatment
demonstrated a signiﬁcantly higher tumor burden as assessed from the increasing intensity of the bioluminescent signals over the period
of 28 days. Representative bioluminescence images of mice inoculated with 105 H441GL cells and received two diﬀerent doses of ACAE
oral gavages: 6.25mgkg−1 3d a y s −1 and 31.25mgkg−1 3d a y s −1, respectively (equivalent to 100μg and 500μg, resp.). Both treatment groups
demonstrated a signiﬁcant reduction in tumor burden when compared to the control group, especially in the mice treated with 500μgo f
ACAE. (d) Scatter plots of superﬁcial tumor size over time (measured by calliper) in response to two diﬀerent concentrations of ACAE
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Figure 6: Proposed molecular pathways of ACAE-mediated
anti-cancer eﬀects. ACAE-induced anti-cancer eﬀects could be
attributed to the combined actions of the cessation of DNA
synthesis (cell cycle arrest), apoptosis and anti-migration (later
two being more predominant). The protein expression levels of
key molecules involved are listed in their respective pathways.
Downward and upward arrows depict decreased and increased level
of expression.
found to be anti-inﬂammatory and anti-tumorigenic in
vivo [9, 10]. It is important to note that ACAE used in
this study contains ∼12% oleanolic acid by weight (data
not shown). We speculate that the relatively high OA
concentration in the ACAE contributes to its anti-cancer
properties both in vitro and in vivo. Additionally, a potent
synthetic triterpenoid derivative, 2-cyano-3,12-dioxooleana-
1,9(11)-dien-28-oic acid (CDDO) has been shown to inhibit
the proliferation of various malignant cells independent of
p53 status [31]. This is very similar to our observation
that ACAE inhibits proliferation in H441GL cells with non-
functional p53. The abilities to suppress proliferation and
induceapoptosisinH441GLcellsbyACAEﬁtthepleiotropic
nature of triterpenoids. Thus, it is plausible that the major
anti-cancer attributes of ACAE are derived from its high
content of triterpenoids.
Considering the genetic and epigenetic complexities
of an advanced carcinoma, combined multifunctional
agents/drugs such as ACAE (in this study), triterpenoids,
rexinoids, selective estrogen-receptor modulators (SERMS)
and deltanoids [32–34] could target multiple signaling path-
ways in the prevention and treatment of cancer. Bioactive
ingredients in ACAE (triterpenoids and others) most likely
function through activities including anti-inﬂammatory,
anti-oxidative, immunological and down to transcriptional
modulations on the cells to provide anti-cancer eﬀects. All of
these overall processes are highly relevant to carcinogenesis
and its control via the pleotropic nature of ACAE to
ameliorate the multiple defects in the cells and tissues in
NSCLC oﬀers a greater possibility of success than the use of a
monofunctional agent that targets speciﬁcally a single defect.
Collectively,ourdataindicatedthatACAEcontainsdesir-
able anti-cancer properties. AC has been used extensively
as complementary and alternative medicine (CAM) and
health supplements in Taiwan, and no reported toxicity
in rodents was observed even at a high concentration
of 500mg−1 kg−1 day−1 (unpublished data). Thus, ACAE
reported in this study could represent a potential new class
ofmultifunctionalCAMforthetreatmentofNSCLC.Finally,
weadvocateandendorsetheideaofusingmolecularimaging
as a powerful tool for a more comprehensive pre-clinical
evaluation of CAM agents.
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